Ignite Creation Date:
2024-07-17 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06491719
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-07-01
Brief Title:
A Study on Efficacy and Safety of iNK Cells for CAEBV EBV-HLH After Allo-HSCT
Sponsor:
Beijing Friendship Hospital
Organization:
Beijing Friendship Hospital
Study Overview
Official Title:
A Study on Efficacy and Safety of iNK Cell Infusion in Patients With Chronic Active Epstein-Barr Virus Infection CAEBV and Epstein Barr Virus-induced Haemophagocytic Lymphohistiocytosis EBV-HLH After Allogeneic Hematopoietic Stem Cell Transplantation
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection CAEBV and EBV-associated hemophagocytic lymphohistiocytosis EBV-HLH after allogeneic hematopoietic stem cell transplantation allo-HSCT
Detailed Description:
It is a prospective open-lable study to evaluate the efficacy and safety of iNK cell infusion in CAEBVEBV-HLH patients after allo-HSCT The study will enroll fifteen subjects who will receive ongoing least 4 doses of iNK cells intravenously infusion after allogeneic hematopoietic stem cell transplantation All subjects will assess the incidence of disease relapse and EBV-DNA reactivation up to one year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None